WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsPACCAR Inc (PCAR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 5% more annual revenue ($29.14B vs $27.78B). PCAR leads profitability with a 8.9% profit margin vs 3.3%. PCAR trades at a lower P/E of 24.3x. PCAR earns a higher WallStSmart Score of 54/100 (C-).

MDLN

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 5.0Value: 6.3Quality: 6.8
Piotroski: 4/9

PCAR

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 4.7Quality: 4.5
Piotroski: 1/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDLNUndervalued (+69.5%)

Margin of Safety

+69.5%

Fair Value

$147.84

Current Price

$39.52

$108.32 discount

UndervaluedFair: $147.84Overvalued
PCARSignificantly Overvalued (-24.5%)

Margin of Safety

-24.5%

Fair Value

$103.99

Current Price

$114.31

$10.32 premium

UndervaluedFair: $103.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN2 strengths · Avg: 9.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

PCAR1 strengths · Avg: 9.0/10
Market CapQuality
$60.02B9/10

Large-cap with strong market position

Areas to Watch

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
36.7x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
6.0%3/10

ROE of 6.0% — below average capital efficiency

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

PCAR2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Revenue GrowthGrowth
-8.9%2/10

Revenue declined 8.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bull Case : PCAR

The strongest argument for PCAR centers on Market Cap. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 3.3% margins leave little buffer for downturns.

Bear Case : PCAR

The primary concerns for PCAR are Piotroski F-Score, Revenue Growth.

Key Dynamics to Monitor

MDLN is growing revenue faster at 10.7% — sustainability is the question.

PCAR generates stronger free cash flow (825M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PCAR scores higher overall (54/100 vs 52/100). MDLN offers better value entry with a 69.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

PACCAR Inc

INDUSTRIALS · FARM & HEAVY CONSTRUCTION MACHINERY · USA

PACCAR Inc is an American Fortune 500 company and counts among the largest manufacturers of medium- and heavy-duty trucks in the world. PACCAR is engaged in the design, manufacture and customer support of light-, medium- and heavy-duty trucks under the Kenworth, Peterbilt, Leyland Trucks, and DAF nameplates. PACCAR also designs and manufactures powertrains, provides financial services and information technology, and distributes truck parts related to its principal business.

Want to dig deeper into these stocks?